Volume 129, Issue 5 pp. E187-E193
Laryngology

Phosphorylation of the glucocorticoid receptor alters SMAD signaling in vocal fold fibroblasts

Shigeyuki Mukudai MD, PhD

Shigeyuki Mukudai MD, PhD

From the Department of Otolaryngology–Head and Neck Surgery , NYU Voice Center, New York, New York, U.S.A

Search for more papers by this author
Nao Hiwatashi MD, PhD

Nao Hiwatashi MD, PhD

From the Department of Otolaryngology–Head and Neck Surgery , NYU Voice Center, New York, New York, U.S.A

Search for more papers by this author
Renjie Bing MD

Renjie Bing MD

From the Department of Otolaryngology–Head and Neck Surgery , NYU Voice Center, New York, New York, U.S.A

Search for more papers by this author
Michael Garabedian PhD

Michael Garabedian PhD

the Department of Microbiology , New York University School of Medicine, New York, New York, U.S.A

Search for more papers by this author
Ryan C. Branski PhD

Corresponding Author

Ryan C. Branski PhD

From the Department of Otolaryngology–Head and Neck Surgery , NYU Voice Center, New York, New York, U.S.A

Send correspondence to Ryan C. Branski, PhD, NYU Voice Center, Department of Otolaryngology–Head and Neck Surgery, New York University School of Medicine, 345 East 37th Street, Suite 306, New York, NY 10016. E-mail: [email protected]Search for more papers by this author
First published: 16 October 2018
Citations: 17

Portions of these data were accepted for presentation at the American Laryngological Association, Combined Otolaryngology Spring Meetings, National Harbor, Maryland, U.S.A., April 18–20, 2018.

Funding for this work was provided by the National Institute on Deafness and Other Communication Disorders (NIDCD)/the National Institutes of Health (NIH), (RO1 DC013277 and RO1 DC017397, PI-Branski). The authors have no other funding, financial relationships, or conflicts of interest to disclose.

Abstract

Objectives/Hypothesis

Direct glucocorticoid (GC) injection for vocal fold (VF) scarring has evolved as a therapeutic strategy, but the mechanisms underlying the antifibrotic effects remain unclear. GCs act via the glucocorticoid receptor (GR), which is phosphorylated at multiple serine residues in a hormone-dependent manner to affect bioactivity. We hypothesize that GCs regulate SMAD signaling via GR phosphorylation in vocal fold fibroblasts (VFFs).

Study Design

In vitro.

Methods

Human VFFs were treated with dexamethasone (DM; 10−5–10−7M) ± transforming growth factor (TGF)-β1 (10 ng/mL). RU486 (10−6M) was employed to isolate the regulatory effects of GR. Total GR, Ser211, and Ser203 phosphorylation was examined via sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunocytochemistry. Quantitative polymerase chain reaction was employed to determine GR-mediated effects of DM on genes related to fibrosis.

Results

Total GR and Ser211 phosphorylation was observed predominantly in the nucleus 1 hour after DM administration. DM decreased total GR expression, but Ser203 and Ser211 phosphorylation increased. RU486 limited the effects of DM. SMAD3 and SMAD7 mRNA expression significantly decreased 4 hours after DM administration (P < 0.05); this response was negated by RU486. COL1A1 remained unchanged, and ACTA2 significantly increased following 24 hours of DM treatment (P < 0.05).

Conclusion

DM regulated TGF-β1 signaling via altered SMAD3 and SMAD7 expression. This response was associated with altered GR phosphorylation. These findings provide insight into the mechanisms of steroidal effects on vocal fold repair; ultimately, we seek to enhance therapeutic strategies for these challenging patients.

Level of Evidence

NA Laryngoscope, 129:E187–E193, 2019

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.